ArticleFrontiers in immunology2018
Autoantibodies May Predict Immune-Related Toxicity: Results from a Phase I Study of Intralesional
Article in Frontiers in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 82 citations in OpenAlex.
- A phase I dose-escalation, safety/tolerability, and preliminary efficacy study of the intratumoral administration of GEN0101 in patients with advanced melanoma.Cancer immunology, immunotherapy : CII · 2022Trial
- Predicting response and toxicity to PD-1 inhibition using serum autoantibodies identified from immuno-mass spectrometry.F1000Research · 2020Trial
- Absence of autoantibodies linked to cancer and autoimmune disorders 26 weeks after BNT162b2 boosting in CoronaVac- primed individuals.Human vaccines & immunotherapeutics · 2026Article
- Defining the rules of engagement: B cells, antibodies and cancer control.Cellular & molecular immunology · 2026Review
- Vaccination-enabled immune readiness for checkpoint blockade.Frontiers in immunology · 2026Review
- BCG in the fight against cancer: exploring its applications in diverse tumour types and future directions.Ecancermedicalscience · 2026Review
- Disseminated Bacillus Calmette-Guerin infection following concurrent intravesical BCG therapy and immune checkpoint inhibitior therapy: a case report.BMC infectious diseases · 2025Article
- Cancer vaccines as enablers of immunotherapy.Nature immunology · 2025Review
- Beyond Tuberculosis: The Surprising Immunological Benefits of the Bacillus Calmette-Guérin (BCG) Vaccine in Infectious, Auto-Immune, and Inflammatory Diseases.Pathogens (Basel, Switzerland) · 2025Review
- Topical and Intralesional Treatments for Skin Metastases and Locoregionally Advanced Melanoma.Cancers · 2024Review
- Neutrophil diversity and function in health and disease.Signal transduction and targeted therapy · 2024Review
- Autoimmune PaneLs as PrEdictors of Toxicity in Patients TReated with Immune Checkpoint InhibiTors (ALERT).Journal of experimental & clinical cancer research : CR · 2023Article
- Role of B cells in immune-related adverse events following checkpoint blockade.Immunological reviews · 2023Review
- Autoantibodies involved in primary and secondary adrenal insufficiency following treatment with immune checkpoint inhibitors.Immuno-oncology technology · 2023Review
- Association between Changes in the Patterns of Antinuclear Autoantibodies during Immune Checkpoint Inhibition Therapy and the Development of Severe Immune Related Adverse Events.International journal of molecular sciences · 2022Article
- A B-cell or a key player? The different roles of B-cells and antibodies in melanoma.Pigment cell & melanoma research · 2022Review
- Severe immune-related hepatitis and myocarditis caused by PD-1 inhibitors in the treatment of triple-negative breast cancer: a case report.Annals of translational medicine · 2022Article
- Exploring the Mechanisms Underlying the Cardiotoxic Effects of Immune Checkpoint Inhibitor Therapies.Vaccines · 2022Review
- Type I interferon-mediated tumor immunity and its role in immunotherapy.Cellular and molecular life sciences : CMLS · 2022Review
- Pulmonary adverse events associated with hypertension in non-small cell lung cancer patients receiving PD-1/PD-L1 inhibitors.Frontiers in pharmacology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of advanced melanoma. The first ICI to demonstrate clinical benefit, ipilimumab, targets cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4); however, the long-term overall survival is just 22%. More than 40 years ago intralesional (IL)
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.